Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 4Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Colonic Neoplasms 2Tongue Neoplasms 1Melanoma 1Localized Resectable Adult Primary Liver Cancer 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Sorafenib 3atezolizumab 2Radiotherapy 2Bevacizumab 2tremelimumab 1temsirolimus 1lonafarnib 1liposomal doxorubicin 1infigratinib 1gadolinium ethoxybenzyl DTPA 1fludarabine 1durvalumab 1cabozantinib 1bavituximab 1aldesleukin 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Resveratrol 1Radiosurgery 1Radionuclide Generators 1Radiofrequency Ablation 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1NSC 366140 1Mass Spectrometry 1Immunotherapy 1Immunohistochemistry 1Genetic Testing 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × Chemotherapy, Adjuvant × Clear all
NCT00293436 2012-09-17

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

University of California, San Francisco

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡